Navigation Links
AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
Date:8/12/2008

the Dresden Technical University. In 1995, he received the Galenus-von-Pergamon prize for having developed alkylphospholipids as a new class of anti-tumor agents. Prof. Engel is the author of more than 250 scientific articles, several books and he applied for more than 100 patent applications.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
2. AEterna Zentaris Sells Quebec City Building for $7.1 million
3. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
4. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
5. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
6. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
7. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
8. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Announces Changes to its Management Team
11. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015   Inocucor ... produces sustainable biological accelerators for farmers, has received ... and Trademark Office for its patent application to ... accelerate plant growth and enhance yields on farms ... relates to Inocucor,s live IN-M1 microbial consortium and ...
(Date:7/27/2015)... FORT WORTH, Texas , July 27, 2015 ... Biopreservation Media Market by Type (Home-brew Media, Pre-formulated Media), by ... North America , Europe , ... & Forecast to 2019", The global biopreservation media market was ... grow to around $571.5 million by 2019, at a CAGR ...
(Date:7/27/2015)... , July 27, 2015 IDEXX Laboratories, ... than 8,000 clinics have submitted over 100,000 specimens to ... in just the first 10 days since the breakthrough ... disease (CKD) is a leading cause of suffering and ... submitted specimens are consistent with generally accepted kidney disease ...
(Date:7/25/2015)... ... July 25, 2015 , ... ... refractometer series. It precisely checks and adjusts the surface temperature of the measuring ... In the pharmaceutical industry, data traceability and documentation are key requirements. It is ...
Breaking Biology Technology:Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5It’s T-Time for Refractometers: On-site Temperature Check Now Available 2
... Richard Duffey, M.D., to its LASIK Directory. ... also serves patients from Pensacola, Florida and from ... Mississippi.,Trusted LASIK Surgeons launched its revolutionary Trusted LASIK ... consumers at www.TrustedLASIKSurgeons.com . What sets the ...
... Varian, Inc.,(NasdaqGS: VARI) introduced its new dual wavelength ... proteins. The SuperNova(TM) is the,first dual wavelength diffraction ... It includes innovations in both X-ray,technology and data ... crystals., Single crystal X-ray diffraction is used ...
... Quality and process,improvement efforts gained new momentum ... higher efficiencies fueled by a stagnating economy.,Biopharmaceutical companies ... pipelines are affecting the bottom line, competition for ... brought more scrutiny to R&D,and New Product Development ...
Cached Biology Technology:Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 2Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 3Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 4Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 5Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 6New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses 2Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools 2
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... June 30, 2015 ... the addition of the "Capacitive Fingerprint Sensors ... To this date, fingerprint sensing technology is ... fingerprint sensors are well developed. This patent landscape ... The domain of capacitive fingerprint sensors ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... headway against a major public health threat, Dartmouth College researchers ... records data in real time, a new study in the ... researchers expect to soon convert the prototype, which is smaller ... reusable device that helps to enforce no smoking regulations and ...
... activity data wirelessly for more than a year in early ... National Institutes of Health. In addition to allowing for more ... device represents a potential major step toward cord-free control of ... report is in the April 2013 issue of the ...
... The Massachusetts Life Sciences Center (MLSC) announced a $4.1 ... newly-created Forsyth Center for Salivary Diagnostics (FCSD). The grant ... a facility that will seek to revolutionize the way ... in December, 2012, more than $400,000 in equipment and ...
Cached Biology News:Wireless, implanted sensor broadens range of brain research 2Wireless, implanted sensor broadens range of brain research 3Forsyth Institute receives $4.1 million grant for new center 2Forsyth Institute receives $4.1 million grant for new center 3
... are supplied as 10X concentrated solutions. REact Buffer ... of the REact buffers and one 250 microl ... four 1 ml vials of REact 1 Buffer ... four 1 ml vials of REact 3 Buffer ...
This Malachite Green Phosphate Detection Kit...
Request Info...
Request Info...
Biology Products: